Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
Sign Up to like & getrecommendations! Published in 2023 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izad073
Abstract: BACKGROUND Ustekinumab (UST), a human monoclonal antibody that binds the p40 subunit of interleukin 12 (IL-12) and IL-23, is licensed for induction and maintenance therapy of moderate to severe inflammatory bowel disease (IBD). To date,… read more here.
Keywords: mucosal response; mucosal healing; response; crohn disease ... See more keywords